175 related articles for article (PubMed ID: 21073062)
41. Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.
Li J; Yao J; Shan H; Chen Y; Jiang ZG; Ren JJ; Xu KJ; Ruan B; Yang SG; Wang B; Xie TS; Li Q
Hum Vaccin Immunother; 2015; 11(5):1108-13. PubMed ID: 25607773
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule.
Chen CC; Chang MH; Lee HC; Twu SJ; Safary A
Acta Paediatr Taiwan; 1999; 40(3):157-60. PubMed ID: 10910606
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults.
Tsai IJ; Chang MH; Chen HL; Ni YH; Lee PI; Chiu TY; Safary A
Vaccine; 2000 Oct; 19(4-5):437-41. PubMed ID: 11027806
[TBL] [Abstract][Full Text] [Related]
47. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India.
Shivananda ; Somani V; Srikanth BS; Mohan M; Kulkarni PS
Clin Vaccine Immunol; 2006 Jun; 13(6):661-4. PubMed ID: 16760324
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
[TBL] [Abstract][Full Text] [Related]
49. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China.
Wang ZZ; Li MQ; Wang P; Yang ZX; Wei L; Zeng Y; Li YP; Yan L; Liu XE; Zhuang H
Vaccine; 2016 Feb; 34(8):1034-9. PubMed ID: 26801063
[TBL] [Abstract][Full Text] [Related]
50. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.
Van Der Meeren O; Crasta P; Cheuvart B; De Ridder M
Hum Vaccin Immunother; 2015; 11(7):1726-9. PubMed ID: 25996260
[TBL] [Abstract][Full Text] [Related]
51. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
[TBL] [Abstract][Full Text] [Related]
52. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination.
Baldy JL; de Lima GZ; Morimoto HK; Reiche EM; Matsuo T; de Mattos ED; Sudan LC
Rev Inst Med Trop Sao Paulo; 2004; 46(2):103-7. PubMed ID: 15141282
[TBL] [Abstract][Full Text] [Related]
53. [The comparison of the humoral response among the patients with liver cirrhosis and steatosis of the liver after HBV vaccination].
Koślińska-Berkan E; Kuydowicz J
Przegl Epidemiol; 2006; 60(2):199-203. PubMed ID: 16964670
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
Vesikari T; Finn A; van Damme P; Leroux-Roels I; Leroux-Roels G; Segall N; Toma A; Vallieres G; Aronson R; Reich D; Arora S; Ruane PJ; Cone CL; Manns M; Cosgrove C; Faust SN; Ramasamy MN; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson D; Popovic V; Diaz-Mitoma F;
JAMA Netw Open; 2021 Oct; 4(10):e2128652. PubMed ID: 34636914
[TBL] [Abstract][Full Text] [Related]
56. Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China.
Zhu F; Deckx H; Roten R; Michiels B; Sarnecki M
Pediatr Infect Dis J; 2017 Jan; 36(1):94-101. PubMed ID: 27753794
[TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
[TBL] [Abstract][Full Text] [Related]
58. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children.
Guptan RC; Thakur V; Safary A; Sarin SK
Vaccine; 2002 May; 20(16):2102-6. PubMed ID: 11972979
[TBL] [Abstract][Full Text] [Related]
60. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
